Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
NR1I2 8856 SAQUINAVIR CHEMBL114 PharmGKB
NR1I2 8856 TERBINAFINE CHEMBL822 PharmGKB
NR1I2 8856 ECONAZOLE CHEMBL808 PharmGKB
NR1I2 8856 HYPERFORIN CHEMBL501711 DrugBank 17139284, 17016423
NR1I2 8856 CHEMBL458767 CHEMBL458767 DrugBank 17139284, 17016423
NR1I2 8856 T091317 CHEMBL62136 DrugBank 10592235
NR1I2 8856 CYPROTERONE ACETATE CHEMBL139835 PharmGKB
NR1I2 8856 NAFCILLIN CHEMBL1443 PharmGKB
NR1I2 8856 MICONAZOLE CHEMBL91 PharmGKB
NR1I2 8856 COLFORSIN CHEMBL52606 PharmGKB
NR1I2 8856 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
NR1I2 8856 DIETHYLSTILBESTROL CHEMBL411 PharmGKB
NR1I2 8856 DICLOXACILLIN CHEMBL893 PharmGKB
NR1I2 8856 ISRADIPINE CHEMBL1648 PharmGKB
NR1I2 8856 CHLORPROMAZINE CHEMBL71 PharmGKB
NR1I2 8856 RIFABUTIN CHEMBL444633 PharmGKB
NR1I2 8856 METYRAPONE CHEMBL934 PharmGKB
NR1I2 8856 VALPROIC ACID CHEMBL109 PharmGKB
NR1I2 8856 DOXYCYCLINE CHEMBL1433 PharmGKB
NR1I2 8856 CARBOQUONE CHEMBL443014 PharmGKB
NR1I2 8856 ERLOTINIB CHEMBL553 agonist DrugBank 19733976, 18839173
NR1I2 8856 DOCETAXEL CHEMBL92 binder PharmGKB, DrugBank 15492266
NR1I2 8856 CEPHALEXIN HYDRATE CHEMBL1200544 PharmGKB
NR1I2 8856 CYCLOSPORINE CHEMBL160 PharmGKB
NR1I2 8856 AMOXICILLIN CHEMBL1082 PharmGKB
NR1I2 8856 CEFUROXIME CHEMBL1436 PharmGKB
NR1I2 8856 CARBAMAZEPINE CHEMBL108 PharmGKB
NR1I2 8856 GLYBURIDE CHEMBL472 PharmGKB
NR1I2 8856 PROGESTERONE CHEMBL103 PharmGKB
NR1I2 8856 SPIRONOLACTONE CHEMBL1393 PharmGKB
NR1I2 8856 SULFAMETHAZINE CHEMBL446 PharmGKB
NR1I2 8856 SIMVASTATIN CHEMBL1064 PharmGKB
NR1I2 8856 GRISEOFULVIN CHEMBL562 PharmGKB
NR1I2 8856 PHENYLBUTAZONE CHEMBL101 PharmGKB
NR1I2 8856 VINCRISTINE CHEMBL90555 PharmGKB
NR1I2 8856 SULFISOXAZOLE DIOLAMINE CHEMBL1200321 PharmGKB
NR1I2 8856 PACLITAXEL CHEMBL428647 inducer PharmGKB, DrugBank 18839173
NR1I2 8856 PIOGLITAZONE CHEMBL595 PharmGKB
NR1I2 8856 TROLEANDOMYCIN CHEMBL564085 PharmGKB
NR1I2 8856 BUDESONIDE CHEMBL1370 PharmGKB
NR1I2 8856 PENICILLIN V POTASSIUM CHEMBL1200852 PharmGKB
NR1I2 8856 ISONIAZID CHEMBL64 PharmGKB
NR1I2 8856 BEXAROTENE CHEMBL1023 PharmGKB
NR1I2 8856 SULFINPYRAZONE CHEMBL832 PharmGKB
NR1I2 8856 TOPIRAMATE CHEMBL220492 PharmGKB
NR1I2 8856 MODAFINIL CHEMBL1373 PharmGKB
NR1I2 8856 PHENOBARBITAL CHEMBL40 PharmGKB
NR1I2 8856 NIFEDIPINE CHEMBL193 PharmGKB
NR1I2 8856 RESERPINE CHEMBL772 PharmGKB
NR1I2 8856 IFOSFAMIDE CHEMBL1024 PharmGKB
NR1I2 8856 TAMOXIFEN CHEMBL83 PharmGKB
NR1I2 8856 ARTEMISININ CHEMBL567597 PharmGKB
NR1I2 8856 MINOCYCLINE CHEMBL1434 PharmGKB
NR1I2 8856 CEFACLOR CHEMBL680 PharmGKB
NR1I2 8856 ST. JOHN'S WORT CHEMBL2108102 PharmGKB
NR1I2 8856 RIFAPENTINE CHEMBL1660 PharmGKB
NR1I2 8856 NICARDIPINE CHEMBL1484 PharmGKB
NR1I2 8856 EFAVIRENZ CHEMBL223228 PharmGKB
NR1I2 8856 TROGLITAZONE CHEMBL408 PharmGKB
NR1I2 8856 LANSOPRAZOLE CHEMBL480 PharmGKB
NR1I2 8856 RITONAVIR CHEMBL163 PharmGKB
NR1I2 8856 CLOTRIMAZOLE CHEMBL104 PharmGKB
NR1I2 8856 LOVASTATIN CHEMBL503 PharmGKB
NR1I2 8856 BOSENTAN CHEMBL957 PharmGKB
NR1I2 8856 CEFADROXIL CHEMBL1644 PharmGKB
NR1I2 8856 FLUTAMIDE CHEMBL806 PharmGKB
NR1I2 8856 CEPHRADINE CHEMBL1604 PharmGKB
NR1I2 8856 VINBLASTINE CHEMBL159 PharmGKB
NR1I2 8856 PERMETHRIN CHEMBL1525 PharmGKB
NR1I2 8856 METHADONE CHEMBL651 PharmGKB
NR1I2 8856 VITAMIN E CHEMBL47 DrugBank 16880233, 16603143
NR1I2 8856 PRASTERONE CHEMBL90593 activator DrugBank 17591676
NR1I2 8856 RIFAXIMIN CHEMBL1617 agonist DrugBank 20627999, 17442842
NR1I2 8856 RILPIVIRINE CHEMBL175691 agonist DrugBank 23583259
NR1I2 8856 RIFAMPICIN CHEMBL374478 agonist DrugBank 16480505, 19460945
NR1I2 8856 ETHINYL ESTRADIOL CHEMBL691 agonist DrugBank 17327420

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
NR1I2 rs7643038 G methotrexate metabolism/PK yes The G allele is associated with longer half-life of methotrexate. Allele G is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele A. 27566582 1449188634
NR1I2 rs3814055 T methotrexate metabolism/PK yes The T allele is associated with longer half-life of methotrexate. Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele C. 27566582 1449188641
NR1I2 rs6785049 G methotrexate metabolism/PK yes Concentrations refers to concentration at 48 hrs Allele G is associated with increased concentrations of methotrexate in children with Osteosarcoma as compared to allele A. 27566582 1449188891
NR1I2 rs3732360 CC efavirenz metabolism/PK no Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT. 26779253 1447680859
NR1I2 rs3814057 AA efavirenz metabolism/PK no Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC. 26779253 1447680877
NR1I2 rs7643645 A risperidone metabolism/PK no Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G. 26129906 1448266483
NR1I2 rs12721616 T rosuvastatin metabolism/PK yes Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C. 30100615 1449733085
NR1I2 rs1054190 CC efavirenz metabolism/PK no Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT. 26779253 1447680865
NR1I2 rs3814055 TT temsirolimus metabolism/PK yes The TT genotype was associated with increased half-life of temsirolimus as compared to the CC and CT genotypes. Genotype TT is associated with decreased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes CC + CT. 28676933 1449140029
NR1I2 rs3814055 T carbamazepine metabolism/PK yes This association was only significant in the African American patients and not in Caucasian patients. Allele T is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to allele C. 23252947 981501880
NR1I2 rs7643645 G carbamazepine metabolism/PK yes This association was significant in the whole cohort. As measured by a higher carbamazepine-10-11 epoxide: carbamazepine ratio. Allele G is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A. 23252947 981501851
NR1I2 rs3732356 GG efavirenz metabolism/PK no Plasma levels of efavirenz were not statistically significantly different between TT, GT, GG genotypes of this SNP. Genotype GG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT. 23173844 1184512532
NR1I2 rs2472677 TT atazanavir metabolism/PK yes TT was associated with 17% higher clearance of unboosted atazanavir. Genotype TT is associated with increased metabolism of atazanavir in people with HIV Infections as compared to genotypes CC + CT. 20921307 749069601
NR1I2 rs3842689 GAGAAG/del + del/del nevirapine "dosage","metabolism/PK" yes as measured by decreased area under the concentration time curve and increased apparent oral clearance of the drug. This was not statistically significant after multiple comparison correction. [stat_test: linear regression] Genotypes GAGAAG/del + del/del are associated with increased clearance of nevirapine in people with HIV Infections as compared to genotype GAGAAG/GAGAAG. 22111602 827823690
NR1I2 rs3814055 T pazopanib efficacy yes Allele T is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C. 21576632 1448106937
NR1I2 rs2472677 CT + TT nevirapine "dosage","metabolism/PK" no no association with PK parameters area under the concentration time curve or apparent oral clearance of the drug. [stat_test: univariate and multiple linear regression] Genotypes CT + TT are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype CC. 22111602 827823858
NR1I2 rs2461817 C carbamazepine metabolism/PK yes This association was significant in the whole cohort. As measured by a higher carbamazepine-10-11 epoxide: carbamazepine ratio. However, Allele C was associated with decreased clearance in African American patients (p=0.03, n=30). Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A. 23252947 981501862
NR1I2 rs4688040 T carbamazepine metabolism/PK yes This association was significant in the whole cohort. As measured by a higher carbamazepine-10-11 epoxide: carbamazepine ratio. Allele T is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele G. 23252947 981501871
NR1I2 rs1523130 CT + TT memantine metabolism/PK yes Carriers of the T allele had 16% slower memantine elimination compared to CC homozygotes, as measured by apparent oral clearance. Genotypes CT + TT are associated with decreased clearance of memantine in people with Dementia as compared to genotype CC. 23371894 1183491305
NR1I2 rs7643645 AA risperidone metabolism/PK no No significant difference in dose-adjusted plasma levels of risperidone were seen between the genotypes. Genotype AA is not associated with clearance of risperidone in people with Psychotic Disorders as compared to genotype GG. 23609392 1183699525
NR1I2 rs1523130 C atazanavir metabolism/PK no Allele C is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele T. 18831695 1448617354
NR1I2 rs1523130 CC donepezil metabolism/PK no Genotypes of CC, CT and TT did not influence donepezil clearance in a covariate model. Genotype CC is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype TT. 24433464 1184511076
NR1I2 rs2472677 TT donepezil metabolism/PK no Genotypes of CC, CT and TT did not influence donepezil clearance in a covariate model. Genotype TT is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype CC. 24433464 1184511080
NR1I2 rs7643645 AA donepezil metabolism/PK no Genotypes of AA, AG and GG did not influence donepezil clearance in a covariate model. Genotype AA is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype GG. 24433464 1184511084
NR1I2 rs2461817 AA lamotrigine metabolism/PK no Alleles given as T and G. The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance. Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype CC. 26213157 1448098990
NR1I2 rs3814055 CC lamotrigine metabolism/PK no The concentration was measured as lamotrigine trough concentration / dose normalized by body weight. Included patients had been on lamotrigine monotherapy for at least a month with complete medical records, had normal renal and hepatic functions, and had therapeutic drug monitoring with good compliance. Genotype CC is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT. 26213157 1448099002
NR1I2 rs2472677 CC + CT atazanavir toxicity no atazanavir boosted with ritonavir Genotypes CC + CT is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype TT. 21288825 1184747519
NR1I2 rs3814058 CC repaglinide metabolism/PK yes Comparisons are between groups that are classified by their genotypes at TWO SNPs: rs2276706 AND rs3814058. These results are for volunteers who received repaglinide and placebo. The study was randomized, in two-phase and crossover with a 2-week washout period. Volunteers received placebo or flucloxacillin 2 times daily for 6 days. On day 7 volunteers were given repaglinide and a meal 3 hours later. Venous blood samples were collected before and after repaglinide at multiple time points.The only significant difference was when comparing Group A, the homozygous wild type genotypes (rs2276706 AA/ rs3814058 TT) to Group D, the homozygous variant genotypes (rs2276706 TT/ rs3814058 CC). Genotype CC is associated with decreased metabolism of repaglinide in men as compared to genotype TT. 23807564 1184754529
NR1I2 rs1523130 CC + CT ritonavir metabolism/PK yes Median ritonavir peripheral blood mononuclear cell (PBMC) intracellular trough concentrations were higher for those with the CT or CC genotype, as compared to those with the TT genotype. However, note that this allele was not significantly associated with intracellular concentrations when using univariate or multivariate linear regression analysis (p=0.181 and 0.190, respectively). Also please note alleles have been complemented to the plus chromosomal strand. Genotypes CC + CT are associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT. 24997317 1184748403
NR1I2 rs3814058 CC repaglinide metabolism/PK yes When exposed to flucloxicillin. Comparisons are between groups that are classified by their genotypes at TWO SNPs: rs2276706 AND rs3814058. These results are for volunteers who received repaglinide and flucloxacillin. The study was randomized, in two-phase and crossover with a 2-week washout period. Volunteers received placebo or flucloxacillin 2 times daily for 6 days. On day 7 volunteers were given repaglinide and a meal 3 hours later. Venous blood samples were collected before and after repaglinide at multiple time points.The only significant difference was when comparing Group A, the homozygous wild type genotypes (rs2276706 AA/ rs3814058 TT) to Group D, the homozygous variant genotypes (rs2276706 TT/ rs3814058 CC). Genotype CC is associated with increased metabolism of repaglinide in men as compared to genotype TT. 23807564 1184754582
NR1I2 rs6785049 AA + AG ritonavir metabolism/PK yes The ritonavir peripheral blood mononuclear cell (PBMC) intracellular/plasma trough concentration ratio was higher for those with the AA or AG genotype, as compared to those with the GG genotype. However, note that this allele was not significantly associated with intracellular concentrations when using univariate linear regression analysis (p=0.506). Genotypes AA + AG is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype GG. 24997317 1184748409
NR1I2 rs3814057 CC adalimumab efficacy no After 20 and 30 weeks of treatment, a greater percentage of those with the CC genotype had biological response to treatment as compared to those with the AA or AC genotype. Biological response assessed using change in C-reactive protein (CRP). However, this association did not remain significant after correction for multiple testing (p=0.318) Genotype CC is associated with increased response to adalimumab in people with Crohn Disease as compared to genotypes AA + AC. 25712183 1444936526
NR1I2 rs2276707 CT + TT tacrolimus metabolism/PK yes Patients with the CT or TT genotypes had decreased dose-adjusted trough concentrations of tacrolimus as compared to those with the CC genotype, when considering a cohort from Kiel, Germany (significant after Bonferroni correction). However, no significant results were seen when considering a cohort from Odense, Denmark or when the German and Danish cohorts were combined. Additionally, no significant results were seen when considering trough concentrations (p=0.64, p=0.92 for German, Danish, respectively) or dose (p=0.03, p=0.59) after Bonferroni correction. Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC. 25271728 1185023364
NR1I2 rs6785049 AA efavirenz metabolism/PK no ON EFV-containing therapy for >7 days, absence of interacting drugs, no co-infection, drug intake 12 hrs (+/- 3 hrs) before blood draw, reported medication adherence above 90%. Receive 600 mg EFV once daily. Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG. 26774523 1447680454
NR1I2 rs3814055 CT + TT tacrolimus metabolism/PK yes Male individuals with the CT or TT genotype had increased maximum plasma concentrations (Cmax) and increased area under the concentration curve from time zero to the last quantifiable time point (AUClast) as compared to those with the CC genotype. More specifically, those with the TT genotype had a geometric mean AUClast and Cmax that were 1.72 and 1.54 times greater, respectively, compared with the CC genotype. Genotypes CT + TT is associated with increased concentrations of tacrolimus in healthy individuals as compared to genotype CC. 26882121 1447946985
NR1I2 rs13059232 C cyclophosphamide metabolism/PK no This SNP had a small effect on cyclophosphamide (CPA) metabolite plasma concentrations (4-OH-CPA), but did not reach significance (Bonferroni corrected p-value= 0.0056). Allele C is not associated with metabolism of cyclophosphamide in people with as compared to allele T. 26456622 1446907717
NR1I2 rs10934498 AA irinotecan "toxicity","metabolism/PK" yes The A allele was associated with decreased AUC of SN-38 with a recessive inheritance model (p=0.009), with decreased biliary index in a recessive inheritance model (p=0.017), and decreased risk of grade 3-4 hepatotoxicity in an additive inheritance model (p=0.009). Patients had metastatic colon cancer and received irinotecan-based chemotherapy at the standard dose of 180 mg/m2. Genotype AA is associated with decreased exposure to irinotecan in people with Colonic Neoplasms as compared to genotypes AG + GG. 27116457 1448097420
NR1I2 rs1523130 CC atazanavir metabolism/PK no Looked at CL/F, concentration at 24 hours, and ratios of metabolites M1 and M2 to atazanavir. Genotype CC (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotypes CT + TT. 26892777 1447947686
NR1I2 rs2472677 CT atazanavir metabolism/PK yes Looked at CL/F, concentration at 24 hours, and ratios of metabolites M1 and M2 to atazanavir. Only concentration 24 hours post-dose was significantly lower in subjects with the CT genotype as compared to the CC or TT genotypes. Genotype CT (assigned as deficiency phenotype) is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + TT. 26892777 1447947668
NR1I2 rs6785049 G tacrolimus metabolism/PK no Allele G is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to allele A. 28777242 1448995025
NR1I2 rs2472677 C risperidone metabolism/PK no Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T. 26129906 1448266474
NR1I2 rs2472677 TT atazanavir dosage yes Randomized, controlled trial in which patients were placed into an atazanavir pharmacogenetically-directed dosing arm or a standard dosing arm. The pharmacogenetic arm took into account this variant, ABCB1 rs1045642 and SLCO1B1 rs4149056. A greater percentage of patients in the pharmacogenetic arm had target atazanavir concentrations. Genotype TT is associated with dose of atazanavir in people with HIV Infections. 26174719 1448260859
NR1I2 rs2276707 CC risperidone metabolism/PK yes The clearance of risperidone was found to be 6% higher in patients with the CC genotype compared to patients with the CT and TT genotypes. Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to genotypes CT + TT. 26129906 1448266420
NR1I2 rs1523130 CC risperidone metabolism/PK yes The clearance of risperidone was found to be 33% higher in patients with the CC genotype compared to patients with the CT and TT genotypes. Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression or Substance-Related Disorders as compared to genotypes CT + TT. 26129906 1448266403
NR1I2 rs3814055 CT + TT tacrolimus metabolism/PK yes dose-adjusted concentration 6 month after transplantation Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC. 28777242 1448995012
NR1I2 rs3814055 CT + TT tacrolimus dosage yes Genotypes CT + TT are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC. 28777242 1448995005
NR1I2 rs2276707 T tacrolimus metabolism/PK no Allele T is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C. 28777242 1448995035
NR1I2 rs2276707 TT sunitinib "dosage","toxicity" no as measured by increased time to dose reduction. Not significant after multivariate analysis. Genotype TT is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT. 24874929 1448530413
NR1I2 rs2472677 TT atazanavir metabolism/PK yes Median Ctrough was lower in individuals with the TT genotype in cohort A (N=47) versus CC+CT genotypes (34 ng/mL [IQR, 25–63 ng/mL] vs. 152 ng/mL (IQR, 47–388 ng/mL; P = .001). In cohort B the TT genotype was also associated with sub-therapeutic ATV concentrations (<150 ng/mL). Genotype TT is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + CT. 18831695 1448617361
NR1I2 rs6785049 GG sirolimus metabolism/PK yes The GG genotype was associated with increased AUC of sirolimus + temsirolimus as compared to the AA and AG genotypes. Genotype GG is associated with increased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG. 28676933 1449140022
NR1I2 rs3814055 CT + TT tacrolimus metabolism/PK no Patients were taking 10mg/day of prednisolone. Genotypes CT + TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC. 29733390 1449749382
NR1I2 rs6785049 AG + GG tacrolimus metabolism/PK no Patients were taking 10mg/day of prednisolone. Patients with the GG genotype had a significantly higher increase in C0/D during steroid tapering as compared to those with the AA genotype (p=0.02); only a trend was observed when comparing AG vs AA genotypes. Genotypes AG + GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA. 29733390 1449749389
NR1I2 rs2276707 CT + TT tacrolimus metabolism/PK no Patients were taking 10mg/day of prednisolone. Patients with the TT genotype had a significantly lower decrease in C0/D during steroid tapering as compared to those with the CC genotype. Genotypes CT + TT is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC. 29733390 1449749395
NR1I2 rs3842689 GAGAAG tacrolimus metabolism/PK no Concentrations were assessed at Day 7 and 15, Month 1, 3 and 6, and Year 1, 2, 3 and 5. At year 1, there was a significant association (p=0.023). Allele GAGAAG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele del. 28945481 1449165851
NR1I2 rs3814055 T tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. 29318894 1449162841
NR1I2 rs3814057 A tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. This is a proxy SNP for rs2276707. Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. 29318894 1449162856
NR1I2 rs6785049 G tacrolimus metabolism/PK no This study was attempting to validate reported variants and tacrolimus trough concentration in a large population of African American and European American kidney transplant patients. Allele G is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele A. 29318894 1449162849
NR1I2 rs2472682 C warfarin dosage no Warfarin dose requirement was defined as the reported daily dose at 3 months following treatment initiation. Allele C is not associated with dose of warfarin as compared to allele A. 29298995 1449164085
NR1I2 rs2461817 C etonogestrel "efficacy","metabolism/PK" no Corrected P-value cutoff of 5.0E-4 was not met. Allele C is associated with increased steady-state concentration of etonogestrel in women as compared to allele A. 30870275 1450375853
NR1I2 rs1464602 GG efavirenz metabolism/PK no Plasma levels of efavirenz were not statistically significantly different between the GG, AG, AA genotypes of this SNP. Alleles have been complemented to the plus chromosomal strand. Genotype GG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype AA. 23173844 1184512548
NR1I2 rs2472677 CC efavirenz metabolism/PK no Plasma levels of efavirenz were not statistically significantly different between the CC, CT, TT genotypes of this SNP. Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT. 23173844 1184512540
NR1I2 rs6785049 AG efavirenz metabolism/PK no Plasma levels of efavirenz were not statistically significantly different between the GG and AG genotypes of this SNP. Genotype AG is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype GG. 23173844 1184512544
NR1I2 rs3732359 GG voriconazole metabolism/PK yes in patients with hematopoietic stem cell transplantation and hematological malignancies. Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA. 31932875 1451122208
NR1I2 rs6785049 GG voriconazole metabolism/PK yes in patients with hematopoietic stem cell transplantation and hematological malignancies. Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA. 31932875 1451122177
NR1I2 rs1523130 CC + CT nevirapine "dosage","metabolism/PK" no no association with PK parameters area under the concentration time curve or apparent oral clearance of the drug. [stat_test: univariate and multiple linear regression] Genotypes CC + CT are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT. 22111602 827823838
NR1I2 rs1054191 GG efavirenz metabolism/PK no Genotype GG is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG. 26779253 1447680871
NR1I2 rs2461817 AA voriconazole metabolism/PK yes in patients with hematopoietic stem cell transplantation and hematological malignancies. Genotype AA is associated with decreased concentrations of voriconazole as compared to genotype AC. 31932875 1451122200
NR1I2 rs3814057 CC voriconazole metabolism/PK yes in patients with hematopoietic stem cell transplantation and hematological malignancies. "Loading dose, TB, PCT level, and PXR rs3814057 polymorphism were independent influencing factors of VCZ Cssmin in the analysis of multivariate linear regression." Genotype CC is associated with increased concentrations of voriconazole as compared to genotypes AA + AC. 31932875 1451122160
NR1I2 rs7643645 AA voriconazole metabolism/PK yes in patients with hematopoietic stem cell transplantation and hematological malignancies. Genotype AA is associated with increased concentrations of voriconazole as compared to genotypes AG + GG. 31932875 1451122204
NR1I2 rs12721616 CC efavirenz metabolism/PK no Plasma levels of efavirenz were not statistically significantly different between the CC and TT genotypes of this SNP. Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype TT. 23173844 1184512536
NR1I2 rs2276706 GG repaglinide metabolism/PK yes Comparisons are between groups that are classified by their genotypes at TWO SNPs: rs2276706 AND rs3814058. These results are for volunteers who received repaglinide and placebo. The study was randomized, in two-phase and crossover with a 2-week washout period. Volunteers received placebo or flucloxacillin 2 times daily for 6 days. On day 7 volunteers were given repaglinide and a meal 3 hours later. Venous blood samples were collected before and after repaglinide at multiple time points. The authors evaluated differences in repaglinde metabolism in different genotype combinations. The only significant difference was when comparing Group A, the homozygous wild type genotypes (rs2276706 AA/ rs3814058 TT) to Group D, the homozygous variant genotypes (rs2276706 TT/ rs3814058 CC). Genotype GG is associated with decreased metabolism of repaglinide in men as compared to genotype AA. 23807564 1184754523
NR1I2 rs2276706 GG repaglinide metabolism/PK yes When exposed to flucloxicillin. Comparisons are between groups that are classified by their genotypes at TWO SNPs: rs2276706 AND rs3814058. These results are for volunteers who received repaglinide and flucloxacillin. The study was randomized, in two-phase and crossover with a 2-week washout period. Volunteers received placebo or flucloxacillin 2 times daily for 6 days. On day 7 volunteers were given repaglinide and a meal 3 hours later. Venous blood samples were collected before and after repaglinide at multiple time points. The only significant difference was when comparing Group A, the homozygous wild type genotypes (rs2276706 AA/ rs3814058 TT) to Group D, the homozygous variant genotypes (rs2276706 TT/ rs3814058 CC). Genotype GG is associated with increased metabolism of repaglinide in men as compared to genotype AA. 23807564 1184754574
NR1I2 rs2472677 TT isoniazid metabolism/PK yes This variant is associated with increased AUC of isoniazid at week 8. Genotype TT is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CC + CT. 30779340 1450807575